Bristol Discontinues Tequin, Citing Lack Of Commercial Potential
This article was originally published in The Pink Sheet Daily
Executive Summary
The antibiotic was the subject of recent safety concerns.
You may also be interested in...
Sanofi’s Ketek Is New Target Of Congressional Scrutiny Of FDA
Sen. Grassley requests that senior CDER staff address allegations of inappropriate approval of Sanofi-Aventis’ antibiotic Ketek in May 1 letter.
Sanofi’s Ketek Is New Target Of Congressional Scrutiny Of FDA
Sen. Grassley requests that senior CDER staff address allegations of inappropriate approval of Sanofi-Aventis’ antibiotic Ketek in May 1 letter.
Tequin Merits Black Box Reconsideration For Dysglycemia, Editorial Says
Bristol’s gatifloxacin is “strongly associated with subsequent hospital care for hypoglycemia and hyperglycemia,” NEJM study finds.